Welcome to our dedicated page for CELLBXHEALTH PLC news (Ticker: ANPCY), a resource for investors and traders seeking the latest updates and insights on CELLBXHEALTH PLC stock.
CelLBxHealth plc, formerly known as ANGLE plc and represented in the United States as ANGLE PLC S/ADR (symbol ANPCY), regularly issues news updates that describe its progress in circulating tumour cell (CTC) intelligence and liquid biopsy. Company announcements highlight developments around its Parsortix® platform, collaborations with pharmaceutical and medtech partners, and strategic decisions affecting its business direction and branding.
News items often cover clinical and scientific milestones, such as proof-of-concept studies in indications like glioblastoma and integrations of the Parsortix workflow with established diagnostic platforms, including Roche Tissue Diagnostics’ BenchMark ULTRA system. Releases also describe participation in major oncology and drug development conferences, where the company presents data on CTC detection, biomarker analysis and potential applications in areas such as antibody-drug conjugate development.
Investors and researchers following ANPCY-related news will also see updates on commercial contracts and collaborations. The company has reported completing contracts with large pharmaceutical companies, ongoing services agreements with biopharma partners, and a collaboration with Myriad Genetics to adapt an existing tissue-based cancer test to a CTC-based format using Parsortix. Interim results and strategy updates provide context on revenue mix between pharma services and product sales, as well as commentary on external market conditions.
Corporate governance and board or management changes are another recurring theme. Recent announcements include the transition from ANGLE plc to CelLBxHealth plc, the appointment of an Executive Chairman, subsequent changes to the board, and later the appointment of a Chief Executive Officer and additional non-executive directors. These updates are presented alongside information on funding plans and cash runway.
For readers tracking ANPCY, the news stream offers a consolidated view of how CelLBxHealth is advancing CTC-based technologies, engaging with global partners, and refining its strategy in response to scientific opportunities and market conditions.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has updated on its laboratory accreditation and ovarian cancer study. The company has submitted its accreditation requests for its clinical laboratories in the US and UK. However, supply chain issues have delayed the analysis of ovarian cancer study samples, now expected to finalize in H1 2022. Despite these challenges, ANGLE remains optimistic about obtaining FDA clearance for its Parsortix system, designed to harvest cancer cells from blood, while continuing discussions with the FDA regarding its regulatory decision.
ANGLE plc announced significant findings from a study on non-small cell lung cancer (NSCLC) patients with EGFR mutations treated with Osimertinib. The research, led by Prof. Evi Lianidou, highlights the importance of analyzing both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) for understanding drug resistance mechanisms. The study revealed elevated DNA methylation in cancer-related genes at disease progression, suggesting a link between these alterations and Osimertinib resistance. Liquid biopsies offer safer, cost-effective longitudinal monitoring of cancer evolution, supporting precision medicine initiatives.
ANGLE plc (OTCQX:ANPCY) has announced the issuance of 6,666 new ordinary shares following the exercise of employee options. These shares will rank equally with existing shares, expanding the total to 235,143,050 shares. An application for admission to trading on AIM has been made, expected to take effect on December 30, 2021. The company is recognized for its innovative liquid biopsy technology, particularly the Parsortix system, which captures circulating tumor cells for various analyses, showcasing a commitment to advancing cancer diagnostics and treatment.
ANGLE plc (OTCQX: ANPCY) announced the issuance of 20,000 new ordinary shares following the exercise of employee options, raising the total number of shares to 235,136,384. These shares will commence trading on the London Stock Exchange's AIM on December 7, 2021. The shares rank equally with existing shares. ANGLE focuses on liquid biopsy solutions with its Parsortix system, which captures circulating tumor cells for analysis, supporting advances in cancer diagnostics.
ANGLE plc announces the publication of research from the Medical University of Vienna, demonstrating the effectiveness of its Parsortix system in analyzing circulating tumor cells (CTCs) in non-small cell lung cancer (NSCLC) patients. The study reveals that CTCs with cancer stem cell properties correlate with worse patient outcomes. The Parsortix system achieves a capture rate of up to 80%, surpassing competing systems, and supports RNA analysis for prognostic purposes. The research underscores the potential of CTCs in clinical management and drug discovery.
ANGLE plc announced the issuance of 50,000 new ordinary shares following the exercise of employee options. This move will increase the total number of ordinary shares to 235,116,384. The new shares are set to be admitted to trading on AIM, with the start date expected to be December 2, 2021. ANGLE's Parsortix® system, a key technology for liquid biopsy, is under FDA review for use in metastatic breast cancer patients, while a successful clinical study for an ovarian cancer triage test showed remarkable 95.1% accuracy.
ANGLE plc (OTCQX:ANPCY) has issued 22,667 new ordinary shares following the exercise of employee options, increasing its total shares to 235,066,384. These shares will rank equally with existing shares, and trading is set to commence on November 23, 2021. The company is known for its liquid biopsy technologies, specifically the Parsortix system, which harvests circulating tumor cells (CTCs) for cancer analysis. ANGLE's advancements in cancer diagnostics and established collaborations with renowned medical institutions support its innovative approaches in healthcare.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has appointed Todd Druley, M.D., PhD as Chief Medical Officer, based in the U.S. Dr. Druley, a prominent oncologist with significant experience in molecular diagnostics, previously served at ArcherDX, which was acquired for up to $1.4 billion. His expertise will guide ANGLE's diagnostics development, regulatory processes, and commercial strategies, particularly enhancing the Parsortix system's applications. ANGLE aims to launch its first laboratory-developed test and expand its clinical market offerings.
ANGLE plc (OTCQX: ANPCY) announced the approval of 3,000,000 LTIP options and 4,942,500 staff share options under its existing plans. These options are designed to enhance shareholder value, tied to performance metrics over three years. As of now, the company holds options over 32,406,146 Ordinary Shares, approximately 12.1% of its share capital. The share options will have specific performance conditions and will vest based on the CAGR of share price. The expiration date for certain existing options has been extended to November 17, 2022.
ANGLE plc (OTCQX:ANPCY) has issued 70,000 new ordinary shares following the exercise of employee options. These shares, valued at £0.10 each, will rank pari passu with existing shares and are set to be admitted to AIM on November 18, 2021. This raises the total number of ordinary shares to 235,043,717. ANGLE specializes in liquid biopsy technologies, focusing on cancer diagnostics, and aims for FDA clearance for its Parsortix system, which has shown promising results in clinical trials for metastatic breast cancer and ovarian cancer.